RELATED CONTENT
NEWS
- In bone drug quandary, FDA seeks panel's advice on safety, 'drug holidays'
- EU reprieve for Actos as CHMP concludes benefits outweigh risks in selected patients
- Austerity takes off gloss from Basilea's Toctino forecasts
- Comparative efficacy should have a "formal role in drug licensing"

